Biotech, Food & Drug

HB Ad Slot
HB Mobile Ad Slot

In today’s hyper-aware environment, concerns about food and drug safety are paramount for both companies and consumers.  The Food and Drug Administration (FDA) and the US Department of Agriculture (USDA) regulates the areas of biotech, food, and drug law. Additionally, laws including the 21st Century Cures Act, and cGMP (Current Good Manufacturing Processes), regulate industry standards/norms in food, cosmetics, and other industry-sectors. Visitors to the National Law Review will find the latest analysis of news, legislation, and upcoming cases/litigation as it relates to this area of law.

With researchers searching for new energy solutions and other developments in biotech, visitors to the NLR will have the opportunity to read content surrounding biosimilars, natural fuel production, medical devices, biotechnology, nanotechnology and materials, and the pharmaceuticals industry. Additionally, content relating to food and drug laws, limits on chemical use in cosmetic products, and other general health/safety topics are covered by the National Law Review and are updated regularly. Additionally, food safety and imports to the United States are also discussed as they become relevant. 

In addition to general health, science, and food/drug, the industry is also closely related to many of the issues related to intellectual property law. New applications for patents, intellectual property, licensing laws, and other areas which are governed by the PTAB court, often crossover into the industry.

New developments in legislation, including the legalization of recreational marijuana has created a new area ripe for legal analysis.  Regulations on how recreational marijuana can be advertised and marketed, distributed and the kind of insurance coverage necessary for dispensaries.  Additionally, employer drug-testing and marijuana statutes have been a hot area of litigation covered by the National Law Review.  

General practices in marketing standards, compliance of federal and state laws/legislation, licensing collaborations, and news related to bringing new products to the market, in the US and abroad, are among the areas visitors to NLR will read about daily. Drug pricing, changes in production standards, regulatory compliance, food safety and handling, drug laws (legalization of marijuana, both recreational and medicinal in the workplace), and labeling and nutritional requirements, are among the many topics covered by the National Law Review daily.

Visitors will always find the latest, up-to-date, most comprehensive coverage on the site. And, news and stories which affect the US, companies which are regulated in the industry, and multinational/international companies, are detailed regularly for NLR readers.

National Law Review Cannabis TwitterFor hourly updates on the latest news about biotech, food & drug, and cannabis laws, regulations, and legislation, be sure to follow our Cannabis X (formerly Twitter) feed, and sign up for complimentary e-news bulletins.

Recent Biotechnology, Food & Drug Administration FDA News

Title
Publication Date Organization Sort descending
May
22
2011
DOE Announces Funding for U.S.-India Joint Clean Energy Research and Development Center U.S. Department of Energy
Sep
19
2011
The Truth about Clean Energy Jobs U.S. Department of Energy
Feb
25
2011
Department of Energy Finalizes $96.8 Million Loan Guarantee for Oregon Geothermal Project U.S. Department of Energy
May
24
2011
Department of Energy Offers Conditional Commitment for Loan Guarantee to Support Solar Generation Project in Nevada U.S. Department of Energy
Sep
20
2011
A Liquid Layer Solution for the Grid U.S. Department of Energy
Jan
18
2012
As Electric Vehicles Take Charge, Costs Power Down U.S. Department of Energy
Mar
8
2011
Department of Energy Offers Conditional Commitment for a Loan Guarantee to Support Maine Wind Project U.S. Department of Energy
Apr
12
2011
U.S. Department of Energy and Qatar Sign Agreement to Strengthen Cooperation on Clean Energy U.S. Department of Energy
Jan
21
2015
Teva v. Sandoz pt.II– The Dissent And The Zone Of Uncertainty Schwegman, Lundberg & Woessner, P.A.
Mar
19
2015
Enzo Biochem V. Applera Corp. – When “Words Can Hurt You” Schwegman, Lundberg & Woessner, P.A.
Mar
22
2016
Sequenom Files Petition for Cert. After Invalidation of Cff Patent Schwegman, Lundberg & Woessner, P.A.
Mar
16
2020
INO v. Praxair – Time for the Supreme Court to Step Up to the Plate? Schwegman, Lundberg & Woessner, P.A.
Mar
17
2020
Illumina v. Ariosa – The “Bucket” to be in Schwegman, Lundberg & Woessner, P.A.
Apr
13
2011
Myriad Oral Arguments – Section 101 vs. Chemistry 101? Schwegman, Lundberg & Woessner, P.A.
Jul
16
2013
Patentability Issues for Plants in the European Patent Office (EPO) Schwegman, Lundberg & Woessner, P.A.
Nov
18
2013
Ohio Willow Wood Co. v. Alps South, LLC – Inequitable Conduct Lives! Schwegman, Lundberg & Woessner, P.A.
Mar
21
2014
United States Patent & Trademark Office (USPTO) Guidelines Blur “Natural” And “Novel” Products Schwegman, Lundberg & Woessner, P.A.
Aug
4
2014
Ignorance is Bliss – for Teva re: Structural Obviousness in Patent Cases Schwegman, Lundberg & Woessner, P.A.
Jun
13
2019
Senate Subcommittee Hearing of Patent Eligibility Wrap Up – Now What? Schwegman, Lundberg & Woessner, P.A.
Apr
16
2015
Genetic Engineering Makes the Blacklist Schwegman, Lundberg & Woessner, P.A.
Jun
12
2015
Ariosa v. Sequenom – Novel Genetic Analysis Fails The Mayo Test Schwegman, Lundberg & Woessner, P.A.
Oct
11
2019
OSI v. Apotex – Christmas in October! Schwegman, Lundberg & Woessner, P.A.
Sep
26
2016
Vanda v. Roxane Labs. – Are Two Natural Laws Better Than One? Schwegman, Lundberg & Woessner, P.A.
Jan
30
2024
China’s Supreme People’s Court Upholds 79 Million RMB Win for Château Lafite Rothschild in Wine Trademark Case Schwegman, Lundberg & Woessner, P.A.
Sep
24
2012
Appellate Court Ruling Permits Continued NIH Funding of Embryonic Stem Cell Research Schwegman, Lundberg & Woessner, P.A.
Oct
11
2012
Federal Circuit to Address Computer-Implemented Inventions En Banc Schwegman, Lundberg & Woessner, P.A.
Feb
17
2013
Biotech’s Public Relations Problems Continue Schwegman, Lundberg & Woessner, P.A.
Apr
23
2013
Marks & Clerk Releases Life Sciences 2013 Report Schwegman, Lundberg & Woessner, P.A.
 

NLR Logo

We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up to receive our free e-Newsbulletins

 

Sign Up for e-NewsBulletins